Leukemia & lymphoma/Leukemia and lymphoma,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 12
Published: Dec. 3, 2024
Advances
in
treating
classic
Hodgkin
lymphoma
(cHL)
have
improved
cure
rates,
with
overall
survival
exceeding
80%,
resulting
a
growing
population
of
survivors
at
risk
long-term
complications,
particularly
cardiac
and
pulmonary
toxicity.
Bleomycin,
key
component
combination
chemotherapy,
is
associated
bleomycin-induced
toxicity
(BPT).
Using
label-free
quantification
nano
liquid
chromatography-tandem
mass
spectrometry,
protein
expression
diagnostic
samples
from
patients
without
BPT
was
compared.
Results
showed
differential
disrupted
cellular
pathways,
suggesting
biological
differences
risk.
Immunohistochemical
analysis
revealed
higher
JAK3,
BID,
MMP9,
lower
CD20,
TPD52,
PIK3R4
BPT.
High
BID
low
CD20
were
inferior
survival,
while
high
JAK3
linked
to
poorer
progression-free
survival.
These
findings
highlight
altered
profiles
pretreatment
cHL
biopsies
development.
BIO Integration,
Journal Year:
2025,
Volume and Issue:
6(1)
Published: Jan. 1, 2025
Pulmonary
fibrosis
(PF)
is
a
progressive
interstitial
lung
disease
characterized
by
excessive
extracellular
matrix
deposition
and
tissue
scarring,
leading
to
impaired
function
respiratory
failure.
Although
current
treatments,
such
as
pirfenidone
nintedanib,
slow
progression,
they
fail
completely
halt
or
reverse
fibrosis.
Therefore,
innovative
therapeutic
strategies
are
needed.
Targeted
drug
delivery
systems
(TDDSs)
emerging
promising
solutions.
Biomaterials
play
critical
roles
in
these
enhancing
specificity,
availability,
efficacy,
while
minimizing
systemic
toxicity.
The
most
notable
biomaterials
include
nanotechnology-based
systems,
including
liposomes
polymeric
nanoparticles,
which
facilitate
penetration
release
fibrotic
tissues.
Hydrogels
have
three-dimensional
structures
providing
controlled
sustained
at
inflammation
sites,
therefore
particularly
valuable
PF
treatment.
Furthermore,
biological
carriers
stem
cells
vesicles
biocompatibility
anti-inflammatory
effects
that
improve
outcomes.
Despite
the
potential
of
clinical
translation
hindered
several
challenges,
immune
clearance,
stability
platforms,
optimization
retention
within
diseased
Interdisciplinary
approaches
integrating
precision
medicine
with
advancements
may
provide
solutions
opening
new
avenues
for
This
review
discusses
developments
targeted
PF,
emphasizing
importance
biomaterials,
mechanisms
barriers
involved
pulmonary
delivery,
future
perspectives
overcoming
limitations.
ultimate
goal
patient
outcomes
revolutionizing
approach
treatment
through
advanced
technologies.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(9), P. 4744 - 4744
Published: April 26, 2024
Cannabidiol
(CBD)
is
a
non-psychoactive
compound
derived
from
Cannabis
sativa.
It
has
demonstrated
promising
effects
in
combating
inflammation
and
holds
potential
as
treatment
for
the
progression
of
chronic
inflammation.
However,
clinical
application
CBD
limited
due
to
its
poor
solubility
bioavailability.
This
study
introduces
an
effective
method
preparing
CBD-loaded
solid
lipid
nanoparticles
(CBD-SLNs)
using
combination
low-energy
hot
homogenization
ultrasonication.
We
enhanced
this
process
by
employing
statistical
optimization
with
response
surface
methodology
(RSM).
The
optimized
CBD-SLN
formulation
utilizes
glyceryl
monostearate
primary
component
nanocarrier.
screened
tool
managing
Stable,
uniformly
dispersed
spherical
size
123
nm,
charge
−32.1
mV,
encapsulation
efficiency
95.16%,
drug
loading
2.36%
were
obtained.
CBD-SLNs
exhibited
sustained
release
properties,
ensuring
prolonged
controlled
delivery,
which
could
potentially
amplify
therapeutic
effects.
Additionally,
we
observed
that
significantly
reduced
both
reactive
oxygen
nitrogen
species
proinflammatory
cytokines
chondrocyte
macrophage
cell
lines,
these
inhibitory
being
more
pronounced
than
those
free
CBD.
In
conclusion,
superiority
over
CBD,
highlighting
delivery
system
Drug Development and Industrial Pharmacy,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 18
Published: Feb. 18, 2025
Objective
This
review
aims
to
explore
innovative
therapeutic
strategies,
with
a
particular
focus
on
recent
advancements
in
drug
delivery
systems
using
bioinspired
nanomaterials
such
as
solid
lipid
nanoparticles
(SLNs)
and
nanostructured
carriers
(NLCs)
for
the
Idiopathic
pulmonary
fibrosis
(IPF).
